Natera is in a powerful uptrend, with the stock up 65.2% over the past year, significantly outperforming the S&P 500's 20.6% gain. The current price of $269.95 sits at 93.7% of its 52-week range (low $131.81, high $288.04), indicating strong momentum and a position near the upper end of its yearly range. This suggests the market is pricing in continued positive catalysts, though it also raises the risk of short-term overextension. Short-term momentum is exceptionally strong, with the stock surging 24.7% in the past month and 39.8% over the past three months, far outpacing the S&P 500's 4.1% and 11.1% gains, respectively. This acceleration from the longer-term trend signals a potential breakout phase, supported by a relative strength of 20.6% versus the market over one month. However, the stock's beta of 1.505 indicates 50.5% more volatility than the market, so such rapid gains could be followed by sharp pullbacks. Key resistance lies at the 52-week high of $288.04; a breakout above this level would signal a continuation of the uptrend and likely attract further buying. Support is at the 52-week low of $131.81, though the stock is far above that. The recent price action shows a strong rally from the June lows near $213, with volume averaging 969,703 shares, suggesting conviction behind the move. A break below $260 (recent support) could indicate a short-term correction, but the overall trend remains bullish.

Natera's revenue trajectory is accelerating, with Q4 2025 revenue of $665.5 million growing 39.8% year-over-year, up from 29.5% growth in Q4 2024. Product revenue of $661.2 million dominates, while licensing and other contributed $4.3 million. The multi-quarter trend shows consistent acceleration from 29.5% in Q4 2024 to 39.8% in Q4 2025, driven by strong adoption of Signatera and Prospera tests. This growth trajectory supports the investment case for a company scaling into profitability. Natera achieved GAAP profitability in Q4 2025, reporting net income of $47.3 million (EPS $0.35) compared to a net loss of $53.8 million in Q4 2024. Gross margin expanded to 67.1% from 62.9% a year ago, reflecting operating leverage and mix shift toward higher-margin tests. Operating margin improved to -3.4% from -13.6%, signaling a clear path to sustained profitability. The company's balance sheet is strong, with $1.08 billion in cash and a debt-to-equity ratio of just 0.125, indicating minimal leverage. Free cash flow turned positive at $37.8 million in Q4 2025, and trailing twelve-month FCF reached $96.6 million, providing internal funding for growth. ROE improved to 2.8% from negative levels, reflecting the turnaround in profitability.